Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis

OBJECTIVE: The efficacy of the novel interleukin (IL)-23p19 inhibitor guselkumab for psoriatic arthritis (PsA) has recently been demonstrated in two phase 3 trials (DISCOVER-1 & -2) but has not been evaluated vs other targeted therapies for PsA. The objective was to compare guselkumab to targete...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J, McInnes, Iain B, Tam, Lai-Shan, Eaton, Kiefer, Peterson, Steve, Schubert, Agata, Chakravarty, Soumya D, Parackal, Anna, Karyekar, Chetan S, Nair, Sandhya, Boehncke, Wolf-Henning, Ritchlin, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Systematic Review and Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121447/
https://www.ncbi.nlm.nih.gov/pubmed/33844022
http://dx.doi.org/10.1093/rheumatology/keab119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121447/
https://www.ncbi.nlm.nih.gov/pubmed/33844022
http://dx.doi.org/10.1093/rheumatology/keab119

Ejemplares similares